Interim data from a phase II study produced positive safety and efficacy data for bel-sar (belzupacap sarotalocan) for the first-line treatment of patients with early-stage choroidal melanoma. With an average of nine months of follow up, the interim data shows the evaluation of two key clinical endpoints: tumor control and visual acuity preservation using the suprachoroidal route of administration.
Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a new study shows.
